The Latest Breaking News from Maged Shenouda

Relmada Therapeutics Q1 Earnings Call Highlights

Relmada Therapeutics (NASDAQ:RLMD) said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing. On the company’s first-q

MarketBeat · May 13